LL-One (levoleucovorin) / Cox Biosci - LARVOL DELTA

PROSPECT Trial: Pelvic Radiation Therapy Avoided for Most Patients With Intermediate-Risk, Locally Advanced Rectal Cancer (THE ASCO POST) - "Julie R. Gralow, MD...said the approach featured reliable patient selection and enabled treatment optimization. Investigators were able to de-escalate therapy in 91% of patients and identify the 9% who needed treatment escalation, she emphasized during a press briefing."

Media quote

Poorer Survival in Stage III Colon Cancer With Greater Inflammation After Surgery and Prior to Adjuvant Therapy (THE ASCO POST) - P=NA | N=1,494 | "In a study reported in JAMA Oncology...Jeffrey ­Meyerhardt, MD, MPH...and colleagues found that higher levels of inflammatory biomarkers measured after surgery but before starting chemotherapy were associated with poorer survival in patients with stage III colon cancer from the CALGB/SWOG 80702 adjuvant chemotherapy trial."

Clinical data

More Research Needed For Neuropathy (Let’s Win! Pancreatic Cancer) - "Most pancreatic cancer tumors are too advanced at diagnosis for resection, leaving chemotherapy as the mainstay of treatment. Overall survival among those receiving chemotherapy for pancreatic cancer has been inching upward, mostly due to chemotherapeutic regimens like the combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel. But both oxaliplatin and paclitaxel are neurotoxic agents and, unfortunately, peripheral neuropathy is a fairly common side effect, explains gastrointestinal oncologist Allyson Ocean, M.D., co-author of the paper 'Chemotherapy-Induced Peripheral Neuropathy: Pathogenesis and Emerging Therapies,' published in the journal Supportive Care in Cancer. 'We grade the neuropathy-based severity and no two cases are ever the same,' adds Ocean..."

Media quote

Expert Point of View: Laura Goff, MD, MSCI (THE ASCO POST) - "Invited discussant Laura Goff, MD, MSCI...said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic pancreatic cancer."

Media quote